Biotechnology
Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
* Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion * Maintained momentum through consistent operational performance and robust client demand * Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale INC...
2026-01-21 15:20
5534
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insi...
2026-01-21 08:15
6179
Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughput Kinase Inhibitor Screening
HOUSTON, Jan. 20, 2026 /PRNewswire/ -- Sino Biological, Inc. is proud to
announce the launch of its innovativeSwiftFluo® TR-FRET Kinase Assay Kits
2026-01-20 23:00
4534
LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders
BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics f...
2026-01-20 20:00
6851
GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation
SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- On January 9th, GENEIII reaffirmed its global leadership in ergothioneine production and scientific validation at the "Research Without Borders • Tracing the Source with GENEIII" Global Evidence-Based Journey. GENEIII joined forces with core partners to v...
2026-01-20 18:09
4306
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteog...
2026-01-20 15:55
5273
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechno...
2026-01-19 21:00
3426
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owne...
2026-01-19 08:02
9158
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Cha...
2026-01-19 08:00
3853
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held inSan Francisco, the United States, fromJanuary 12 to 15. As one of the most influential annual events in the global healthcare sector, JPM serves as a key platform for the capital...
2026-01-16 21:00
5136
The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification
SHENZHEN, China, Jan. 15, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became the first domestic fermentation products that obta...
2026-01-16 12:23
3332
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...
2026-01-15 22:02
5152
Aphranel Convenes Cadaver Dissection Class in Thailand Successfully
BANGKOK, Jan. 14, 2026 /PRNewswire/ -- The inaugural "Moyom Biotech • Aphranel Global Expert Advisory Panel • Thailand Anatomy Exchange Conference" was successfully convened inThailand. This high-level forum gathered leading experts from multipleAsia-Pacific countries. Through this concentrated ...
2026-01-15 17:51
3532
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...
2026-01-15 12:00
6579
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-v...
2026-01-15 11:34
4558
Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion
SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Yuyu Bio and Mervyn's Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on theUCLA campus, strengthening the company's presence in the United States pet and animal health market. The two companies are now based at Magni...
2026-01-14 22:00
4800
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
* Celltrion outlines a blueprint for innovative drug development built on its antibody expertise * The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 13, 202...
2026-01-14 09:18
4324
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second ...
2026-01-13 20:30
3032
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, in patients with advanced gastric ...
2026-01-13 16:26
4480
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
2026-01-13 11:07
5783
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 308 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 305 media titles]
2026-02-26 19:57
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
9225
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2026-02-20 07:27
8501